home / stock / onct / onct news


ONCT News and Press, Oncternal Therapeutics Inc. From 01/14/21

Stock Information

Company Name: Oncternal Therapeutics Inc.
Stock Symbol: ONCT
Market: NASDAQ
Website: oncternal.com

Menu

ONCT ONCT Quote ONCT Short ONCT News ONCT Articles ONCT Message Board
Get ONCT Alerts

News, Short Squeeze, Breakout and More Instantly...

ONCT - Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned...

ONCT - Oncternal and karolinska Institutet ink research deal for ROR1-targeting cell therapies

Clinical-stage biopharmaceutical company Oncternal Therapeutics (ONCT) has inked a research and development deal with Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK (Natural Killer) cells from the laboratory in...

ONCT - Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies

SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it established a research and development collaboration wit...

ONCT - Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover ...

ONCT - Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the closing of its previously announced public offering on a firm commitment basis of ...

ONCT - Can You Make Money With Penny Stocks? 3 Biotech Stocks To Watch

Biotech Penny Stocks To Watch In December, 2020 Are you paying attention to biotech stocks; penny stocks in particular? If you haven’t looked at the sector yet, then it might be time to. Let me be clear, I’m not talking about the broader healthcare industry. Biotech st...

ONCT - SLS, ONCY, BTU and GENE among midday movers

Gainers: Immutep (IMMP) +166%.SELLAS Life Sciences (SLS) +90%.Neos Therapeutics (NEOS) +65%.Greenwich LifeSciences (GLSI) +51%.Aytu BioScience (AYTU) +34%.Veru (VERU) +34%.Silver Spike Acquisition (SSPK) +32%.8x8 (EGHT) +32%.TG Therapeutics (TGTX) +31%.Peabody Energy (BTU) +29%...

ONCT - Immutep, Greenwich LifeSciences leads healthcare gainers; Xenetic Biosciences, Oncternal Therapeutics among major losers

Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax L...

ONCT - Oncternal Therapeutics slips 24% after upsizes $75M bought deal offering

Oncternal Therapeutics (ONCT) announced that the underwriter agreed to upsize of the previously announced offering and purchase on a firm commitment basis ~16.67M shares of common stock of the Company, at a price to the public of $4.50/share.Underwriters' over-allotment is an additional ...

ONCT - Lloyds Banking Group, QuantumScape leads premarket losers' pack

Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...

Previous 10 Next 10